Optiscan Imaging (OIL) H2 2024 earnings summary

Executive summary

• Achieved major development milestones in FY24, including the reveal of the InVue™ imaging device and a successful $16.7M capital raise to fund growth initiatives.

• Entered a strategic collaboration with Mayo Clinic to develop a robotic surgery-compatible imaging system, expanding clinical applications and US market focus.

• Expanded executive and scientific teams, established a US regional office, and made key leadership hires to support commercialization and regulatory efforts.

• Advanced telepathology and AI projects, with proof-of-concept achieved for the telepathology platform and progress in machine learning for oral cancer imaging.

Financial highlights

• FY24 revenue was $1.16M, down 31% year-over-year due to lower orders from a major OEM partner.

• Other income more than doubled to $2.38M, driven by increased R&D incentive income and grant funding.

• Net loss after tax widened to $6.06M from $4.35M in FY23, reflecting higher R&D and commercial expenses.

• Cash on hand at year-end was $6.1M, up from $0.88M, supported by the capital raise.

• Net assets increased to $13.87M from $3.04M, and working capital improved significantly.

Outlook and guidance

• Plans to continue advancing R&D projects and strategic partnerships, especially with Mayo Clinic, focusing on robotic-assisted breast cancer surgery.

• Increased business development and regulatory activities expected in the US, leveraging new hires and the regional office.

• Ongoing investment in product portfolio expansion and clinical studies to support FDA submissions.